These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
228 related articles for article (PubMed ID: 38520909)
1. Ex vivo drug testing of patient-derived lung organoids to predict treatment responses for personalized medicine. Taverna JA; Hung CN; Williams M; Williams R; Chen M; Kamali S; Sambandam V; Hsiang-Ling Chiu C; Osmulski PA; Gaczynska ME; DeArmond DT; Gaspard C; Mancini M; Kusi M; Pandya AN; Song L; Jin L; Schiavini P; Chen CL Lung Cancer; 2024 Apr; 190():107533. PubMed ID: 38520909 [TBL] [Abstract][Full Text] [Related]
2. Patient derived organoids in prostate cancer: improving therapeutic efficacy in precision medicine. Pamarthy S; Sabaawy HE Mol Cancer; 2021 Sep; 20(1):125. PubMed ID: 34587953 [TBL] [Abstract][Full Text] [Related]
3. Genomic characteristics and drug screening among organoids derived from non-small cell lung cancer patients. Chen JH; Chu XP; Zhang JT; Nie Q; Tang WF; Su J; Yan HH; Zheng HP; Chen ZX; Chen X; Song MM; Yi X; Li PS; Guan YF; Li G; Deng CX; Rosell R; Wu YL; Zhong WZ Thorac Cancer; 2020 Aug; 11(8):2279-2290. PubMed ID: 32633046 [TBL] [Abstract][Full Text] [Related]
4. Development of Patient-Derived Gastric Cancer Organoids from Endoscopic Biopsies and Surgical Tissues. Gao M; Lin M; Rao M; Thompson H; Hirai K; Choi M; Georgakis GV; Sasson AR; Bucobo JC; Tzimas D; D'Souza LS; Buscaglia JM; Davis J; Shroyer KR; Li J; Powers S; Kim J Ann Surg Oncol; 2018 Sep; 25(9):2767-2775. PubMed ID: 30003451 [TBL] [Abstract][Full Text] [Related]
5. Patient-derived organoid culture of gastric cancer for disease modeling and drug sensitivity testing. Zu M; Hao X; Ning J; Zhou X; Gong Y; Lang Y; Xu W; Zhang J; Ding S Biomed Pharmacother; 2023 Jul; 163():114751. PubMed ID: 37105073 [TBL] [Abstract][Full Text] [Related]
6. Implementing patient derived organoids in functional precision medicine for patients with advanced colorectal cancer. Cartry J; Bedja S; Boilève A; Mathieu JRR; Gontran E; Annereau M; Job B; Mouawia A; Mathias P; De Baère T; Italiano A; Besse B; Sourrouille I; Gelli M; Bani MA; Dartigues P; Hollebecque A; Smolenschi C; Ducreux M; Malka D; Jaulin F J Exp Clin Cancer Res; 2023 Oct; 42(1):281. PubMed ID: 37880806 [TBL] [Abstract][Full Text] [Related]
7. Patient-derived organoids model treatment response of metastatic gastrointestinal cancers. Vlachogiannis G; Hedayat S; Vatsiou A; Jamin Y; Fernández-Mateos J; Khan K; Lampis A; Eason K; Huntingford I; Burke R; Rata M; Koh DM; Tunariu N; Collins D; Hulkki-Wilson S; Ragulan C; Spiteri I; Moorcraft SY; Chau I; Rao S; Watkins D; Fotiadis N; Bali M; Darvish-Damavandi M; Lote H; Eltahir Z; Smyth EC; Begum R; Clarke PA; Hahne JC; Dowsett M; de Bono J; Workman P; Sadanandam A; Fassan M; Sansom OJ; Eccles S; Starling N; Braconi C; Sottoriva A; Robinson SP; Cunningham D; Valeri N Science; 2018 Feb; 359(6378):920-926. PubMed ID: 29472484 [TBL] [Abstract][Full Text] [Related]
8. Modeling Clinical Responses to Targeted Therapies by Patient-Derived Organoids of Advanced Lung Adenocarcinoma. Kim SY; Kim SM; Lim S; Lee JY; Choi SJ; Yang SD; Yun MR; Kim CG; Gu SR; Park C; Park AY; Lim SM; Heo SG; Kim H; Cho BC Clin Cancer Res; 2021 Aug; 27(15):4397-4409. PubMed ID: 34083237 [TBL] [Abstract][Full Text] [Related]
9. Development of a Single-Cell Technique to Increase Yield and Use of Gastrointestinal Cancer Organoids for Personalized Medicine Application. Gao M; Harper MM; Lin M; Qasem SA; Patel RA; Mardini SH; Gabr MM; Cavnar MJ; Pandalai PK; Kim J J Am Coll Surg; 2021 Apr; 232(4):504-514. PubMed ID: 33253861 [TBL] [Abstract][Full Text] [Related]
10. Building consensus on the application of organoid-based drug sensitivity testing in cancer precision medicine and drug development. Xiang D; He A; Zhou R; Wang Y; Xiao X; Gong T; Kang W; Lin X; Wang X; ; Liu L; Chen YG; Gao S; Liu Y Theranostics; 2024; 14(8):3300-3316. PubMed ID: 38855182 [TBL] [Abstract][Full Text] [Related]
11. Micro-Engineered Organoid-on-a-Chip Based on Mesenchymal Stromal Cells to Predict Immunotherapy Responses of HCC Patients. Zou Z; Lin Z; Wu C; Tan J; Zhang J; Peng Y; Zhang K; Li J; Wu M; Zhang Y Adv Sci (Weinh); 2023 Sep; 10(27):e2302640. PubMed ID: 37485650 [TBL] [Abstract][Full Text] [Related]
12. Establishment of patient-derived organoids for guiding personalized therapies in breast cancer patients. Wu H; Wang W; Zhang Y; Chen Y; Shan C; Li J; Jia Y; Li C; Du C; Cai Y; Zhang Y; Zhang S; Wu F Int J Cancer; 2024 Jul; 155(2):324-338. PubMed ID: 38533706 [TBL] [Abstract][Full Text] [Related]
13. Patient-derived functional organoids as a personalized approach for drug screening against hepatobiliary cancers. Li L; Selaru FM Adv Cancer Res; 2022; 156():319-341. PubMed ID: 35961704 [TBL] [Abstract][Full Text] [Related]
14. The combination of breast cancer PDO and mini-PDX platform for drug screening and individualized treatment. Cui Y; Ran R; Da Y; Zhang H; Jiang M; Qi X; Zhang W; Niu L; Zhou Y; Zhou C; Tang X; Wang K; Yan Y; Ren Y; Dong D; Zhou Y; Wang H; Gong J; Hu F; Zhao S; Zhang H; Zhang C; Yang J J Cell Mol Med; 2024 May; 28(9):e18374. PubMed ID: 38722288 [TBL] [Abstract][Full Text] [Related]
15. Organoids as a biomarker for personalized treatment in metastatic colorectal cancer: drug screen optimization and correlation with patient response. Smabers LP; Wensink E; Verissimo CS; Koedoot E; Pitsa KC; Huismans MA; Higuera Barón C; Doorn M; Valkenburg-van Iersel LB; Cirkel GA; Brousali A; Overmeer R; Koopman M; Braat MN; Penning de Vries B; Elias SG; Vries RG; Kranenburg O; Boj SF; Roodhart JM J Exp Clin Cancer Res; 2024 Feb; 43(1):61. PubMed ID: 38414064 [TBL] [Abstract][Full Text] [Related]
16. Pancreatic cancer-derived organoids - a disease modeling tool to predict drug response. Frappart PO; Walter K; Gout J; Beutel AK; Morawe M; Arnold F; Breunig M; Barth TF; Marienfeld R; Schulte L; Ettrich T; Hackert T; Svinarenko M; Rösler R; Wiese S; Wiese H; Perkhofer L; Müller M; Lechel A; Sainz B; Hermann PC; Seufferlein T; Kleger A United European Gastroenterol J; 2020 Jun; 8(5):594-606. PubMed ID: 32213029 [TBL] [Abstract][Full Text] [Related]
17. Personalized drug screening using patient-derived organoid and its clinical relevance in gastric cancer. Zhao Y; Li S; Zhu L; Huang M; Xie Y; Song X; Chen Z; Lau HC; Sung JJ; Xu L; Yu J; Li X Cell Rep Med; 2024 Jul; 5(7):101627. PubMed ID: 38964315 [TBL] [Abstract][Full Text] [Related]
18. An In Vitro System for Evaluating Molecular Targeted Drugs Using Lung Patient-Derived Tumor Organoids. Takahashi N; Hoshi H; Higa A; Hiyama G; Tamura H; Ogawa M; Takagi K; Goda K; Okabe N; Muto S; Suzuki H; Shimomura K; Watanabe S; Takagi M Cells; 2019 May; 8(5):. PubMed ID: 31137590 [TBL] [Abstract][Full Text] [Related]
19. Patient-derived cancer organoids for drug screening: Basic technology and clinical application. Ren X; Chen W; Yang Q; Li X; Xu L J Gastroenterol Hepatol; 2022 Aug; 37(8):1446-1454. PubMed ID: 35771719 [TBL] [Abstract][Full Text] [Related]
20. Circulating tumor cell-derived organoids: Current challenges and promises in medical research and precision medicine. Praharaj PP; Bhutia SK; Nagrath S; Bitting RL; Deep G Biochim Biophys Acta Rev Cancer; 2018 Apr; 1869(2):117-127. PubMed ID: 29360544 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]